Skip to main content
Mesothelioma - Epidemiology and Management
Current Respiratory Medicine Reviews (2011)
  • Patricia Tai
  • Edward Yu, The University of Western Ontario
  • Avi Assouline
  • Kurian Joseph, University of Alberta
Mesothelioma is an uncommon tumor. It has a latency period of 20-40 years. The most important risk factor is asbestos exposure. Prognosis of mesothelioma is generally poor with high case-fatality rate, and research to improve the outcome of this disease is on-going worldwide. Due to its rarity, management by a multidisciplinary team with experience is recommended. Carefully selected patients may benefit from tri-modality (surgery, radiotherapy and chemotherapy) treatment. The management of pleural and peritoneal mesothelioma is summarized in this review. Recent advances in chemotherapy and biologic response modifiers are promising.
  • Asbestos,
  • Epidemiology,
  • Treatment,
  • Mesothelioma,
  • Tri-modality,
  • Surgery,
  • Radiotherapy,
  • Chemotherapy,
  • Pleural mesothelioma,
  • Peritoneal mesothelioma,
  • Malignant meosothelioma
Publication Date
October, 2011
Citation Information
Patricia Tai, Edward Yu, Avi Assouline and Kurian Joseph. "Mesothelioma - Epidemiology and Management" Current Respiratory Medicine Reviews Vol. 7 Iss. 5 (2011)
Available at: